Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03162562
Title The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Recruitment Terminated
Gender female
Phase Phase I
Variant Requirements No
Sponsors OncoQuest Inc.

fallopian tube adenocarcinoma

peritoneal carcinoma

ovary epithelial cancer


Oregovomab + Poly ICLC

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.